To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Sanofi Website

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

respiratory-syncytial-virus

Respiratory syncytial virus

Ensuring overall RSV prevention in every individual Dr. Alia Podcast

RESPIRATORY-SYNCYTIAL-VIRUS

VACCINES

Kuwait taking the lead in RSV protection for all infants in the Middle east

Systematic review and meta-analysis studies across five countries1 
 32 cohort and case-control studies were included in a systematic review, of which 27 were included in the meta-analysis† , comparing nirsevimab and control groups during the 2023-2024 RSV season. Most studies were conducted in inpatient care settings, followed by outpatient settings and emergency rooms.

RSV related hospitalization

<ul>
 <li>Overall, 16 studies reported data on RSV-related hospitalizations in infants aged 0–12 months</li>
 <li>RSV-related hospitalizations were observed in: 
 <ul>
 <li>Nirsevimab group: 1,585 / 85,242 infants</li>
 <li>Control group: 3,978 / 51,893 infants</li>
 </ul></li>
</ul>

<ul>
 <li>In infants 0-12 months, nirsevimab administration is associated with an 83% (OR: 0.17, 95% CI: 0.12–0.23, p&lt;0.0001) reduction in the risk of RSV-related hospitalization</li>
</ul>

ICU admission

<ul>
 <li>Overall, 9 studies reported data on RSV-related ICU admissions in infants</li>
 <li>ICU admissions were observed in: 
 <ul>
 <li>Nirsevimab group: 176 / 79,545 infants</li>
 <li>Control group: 618 / 48,023 infants</li>
 </ul></li>
 <li>Nirsevimab administration is associated with an 81% (OR: 0.19, 95% CI: 0.12–0.29, p&lt;0.0001) reduction in the risk of RSV-related ICU admissions</li>
</ul>

RSV-related LRTI incidence

<ul>
 <li>Overall, 7 studies reported data on RSV-related LRTI incidence in infants.</li>
 <li>RSV-related LRTI were observed in: 
 <ul>
 <li>Nirsevimab group: 392 / 48,303 infants</li>
 <li>Control group: 1,049 / 9,569 infants</li>
 </ul></li>
 <li>Nirsevimab administration is associated with an 75% (OR: 0.25, 95% CI: 0.19–0.33, p&lt;0.0001) reduction in the risk of RSV-related LRTI incidence</li>
</ul>

Limitations

<ul>
 <li>Observational studies may include bias from confounding factors</li>
 <li>Subgroup analyses on gestational age or pre-existing conditions were not performed due to insufficient data</li>
 <li>The effect of nirsevimab on specific outcomes, such as bronchiolitis, was not assessed</li>
 <li>Prioritization and distribution of nirsevimab across regions can limit the generalizability of the findings</li>
 <li>Previous RSV exposure might have influenced the estimates of nirsevimab effectiveness during the 2023-2024 season</li>
 <li>Differences in baseline characteristics can introduce variability in outcomes</li>
</ul>

CONCLUSION&nbsp; 
 Real world evidence consistently shows a significant reduction in RSV-related outcomes among nirsevimab recipients across studies and countries. These findings underscore the importance of infant immunization in alleviating the burden of RSV disease in infants

Nirsevimab demonstrated public health impact
NIRSE-GAL (Spain)3
Reduction of RSV-related LRTI hospitalization in Galicia compared to previous season*

Nirsevimab was:&nbsp;
<ul>
 <li>80.3% effective as reducing RSV-related LRTI hospitalization with oxygen support (95%CI: 54.6-91.5)</li>
 <li>70.7% effective at reducing RSV-related LRTI hospitalization (95%CI: 42.4-85.1)</li>
 <li>46.0% effective at reducing all-cause bronchiolitis or bronchitis hospitalization (95%CI: 6.8-68.7)</li>
 <li>35.2% effective at reducing all-cause LRTI hospitalization (95%CI: - 3.8-59.6)</li>
</ul>

Nirsevimab significantly reduced infant hospitalization for RSV-related LRTI and RSV-related LRTI requiring oxygen compared to previous season
BEAR: Beyfortus Effectiveness Against Medical Attended RSV Events in Infants (USA)4
<ul>
 <li>15,647 out of 31,900 included infants received nirsevimab</li>
 <li>RSV-LRTD were observed in: 
 <ul>
 <li>35 infants from nirsevimab group (6.1/1000 PY)</li>
 <li>462 infants from untreated infants (58.5/1000 PY)</li>
 </ul></li>
</ul>

Among nirsevimab recipients who did experience an RSV LRTD episode, the mean number of medical encounters was significantly lower than among infants who had not received RSV prevention
Nearly half of eligible healthy term infants received nirsevimab during the 2023-2024 season. Compared with non-immunized infants, those who had RSV LRTD after nirsevimab had significantly fewer medical encounters and were less likely to be hospitalized.
NIRSE-CL (Chile)5
<ul>
 <li>Coverage: 97.5% of the new-born group and 90.4% of the infant group have been immunized</li>
</ul>
<figure class="table" style="width:100%;">
 <table class="ck-table-resized">
 <colgroup>
 <col style="width:33.33%;">
 <col style="width:33.33%;">
 <col style="width:33.34%;">
 </colgroup>
 <tbody>
 <tr>
 <td style="background-color:#23004C;border-bottom:5px solid #7A00E6;padding:10px;vertical-align:top;">&nbsp;</td>
 <td style="background-color:#23004C;border-bottom:5px solid #7A00E6;padding:10px;vertical-align:top;">
 Eligible population</td>
 <td style="background-color:#23004C;border-bottom:5px solid #7A00E6;padding:10px;vertical-align:top;">
 Non-eligible population</td>
 </tr>
 <tr>
 <td>Cumulative&nbsp; hospitalization&nbsp; Compared to previous&nbsp; years hospitalizations</td>
 <td>
 1,211&nbsp; 
 15% of 2019&nbsp; 
 26% of 2022&nbsp; 
 20% of 2023</td>
 <td>
 2,892&nbsp; 
 71% of 2019</td>
 </tr>
 <tr>
 <td>Hospitalization in&nbsp; CCU&nbsp; Compared to previous&nbsp; years CCU&nbsp; hospitalization</td>
 <td>
 249&nbsp; 17% of 2019&nbsp; 21% of 2022&nbsp; 12% of 2023</td>
 <td>
 681&nbsp; 118% of 2019&nbsp; (575)</td>
 </tr>
 </tbody>
 </table>
</figure>

<ul>
 <li>In the eligible population, hospitalizations due to RSV in 2024 were significantly lower than those of previous years</li>
 <li>In the eligible population, RSV hospitalizations in CCUs in 2024 were significantly lower than those of previous years</li>
 <li>The mean length of stay for RSV hospitalization is significantly lower in the immunized group (4.19 days) vs the non-immunized group (5.25 days)</li>
</ul>
Nirsevimab was well accepted by parents in Chile and was associated with a significant reduction in the overall public health burden of RSV disease in infants compared to previous years
†3 studies from Spain, 1 from France and 1 from Luxembourg were not included in the meta-analysis as they compared the nirsevimab and control groups over two different RSV seasons (2022-2023 and 2023-2024)

Respiratory syncytial virus

Latest Articles

Ensuring overall RSV prevention in every individual Dr. Alia Podcast

Kuwait taking the lead in RSV protection for all infants in the Middle east

Nirsevimab RWD Metanalysis